Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

被引：0
|
作者：
H. Xu
Q. Gong
F. D. Vogl
M. Reiner
J. H. Page
机构：
[1] Amgen Inc.,Center for Observational Research
[2] Amgen Inc.,Global Biostatistical Science
[3] Amgen Inc.,Hematology/Oncology
[4] Amgen Inc.,Global Biostatistical Science
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Bone pain; Chemotherapy; Pegfilgrastim; Risk factors; G-CSF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：723 / 730
页数：7
相关论文
共 50 条
  • [1] Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim
    Xu, H.
    Gong, Q.
    Vogl, F. D.
    Reiner, M.
    Page, J. H.
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 723 - 730
  • [2] Risk Factors For Bone Pain Among Patients Receiving Myelosuppressive Chemotherapy and Primary Prophylactic Pegfilgrastim
    Xu, Hairong
    Gong, Qi
    Vogl, Florian D.
    [J]. BLOOD, 2013, 122 (21)
  • [3] Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy
    Crawford, J
    [J]. PHARMACOTHERAPY, 2003, 23 (08): : 15S - 19S
  • [4] The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy
    Lyman, G. H.
    Reiner, M.
    Morrow, P. K.
    Crawford, J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (07) : 1452 - 1458
  • [5] Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy
    Andre, Nicolas
    El Kababri, Maria
    Bertrand, Pourroy
    Rome, Angelique
    Coze, Carole
    Gentet, Jean Claude
    Bernard, Jean Louis
    [J]. ANTI-CANCER DRUGS, 2007, 18 (03) : 277 - 281
  • [6] Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
    Shinya Tsuboi
    Tatsuya Hayama
    Katsuhiro Miura
    Akihiro Uchiike
    Daisuke Tsutsumi
    Takashi Yamauchi
    Yoshihiro Hatta
    Susumu Ootsuka
    [J]. Journal of Pharmaceutical Health Care and Sciences, 9
  • [7] Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy
    Tarantino, P.
    Zagami, P.
    Trillo, P.
    Conforti, F.
    Pala, L.
    Morganti, S.
    Ferraro, E.
    Viale, G.
    Duso, B. A.
    D'Amico, P.
    Marra, A.
    Trapani, D.
    De Pas, T. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim
    Moore, Donald C.
    Gebru, Tsion
    Pellegrino, Annie
    Fasan, Adenike
    Patel, Jolly
    Ringley, J. Tanner
    [J]. JOURNAL OF PHARMACY PRACTICE, 2020, 33 (06) : 779 - 783
  • [9] Effect of timing of pegfilgrastim administration on absolute neutrophil count (ANC) trajectory among cancer patients (pts) receiving myelosuppressive chemotherapy (chemo).
    Li, Yanli
    Klippel, Zandra Karina
    Shih, Xiaolong
    Wang, Hong
    Reiner, Maureen
    Page, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Pegfilgrastim is preferred to filgrastim in cancer patients on myelosuppressive chemotherapy treatment regimens
    Viens, P
    Namer, M
    Selle, F
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 738 - 739
12345